Here were my questions to Investor Relations and their response:
What is the purpose of the Singapore re-domicile?
As a long time investor, It makes a little nervous that somehow we are going to lose everything when it is finalized.
Also, since all the self-imposed deadlines for manufacturing and distribution agreements keep getting pushed back, it seems like the other investors are losing confidence as well.
What can you do to get the confidence back and increase the share price?
Hello Mr. xxxxxxxx,
The migration to Singapore provides a number of strategic benefits, including better access to government support, investments and funding, partnerships, access to global business, and more. There is no need for concern on the migration, there are currently no plans to go private, in fact quite the opposite. As we have previously announced we are working with the NYSE America to potentially list on their exchange in the near future.
We have outlined our business plan through various new releases and the investor deck on our corporate website, we have been as transparent as we can be at this time about the GluCurve in regard to the market size and need, manufacturing, distribution, and timeline. But we cannot control the price per share of ALRT or the confidence an individual has in our potential future success. We believe by executing on our business plan we will bring long term value to shareholders and that is what we are focused on doing. We have a very strong relationship with our manufacturer, and the global leader in animal health we are working with.
There is not much information we can provide outside of what has been publicly stated, but I would strongly encourage any current or potential shareholder to reread the past handful of new releases and the investors deck on our website before asking themselves, have the recent delays fundamentally changed anything?
V/r
Joe Stern
Head of Animal Health
Joe.Stern@alrt.com
